PATENT CLAIM ANALYSIS

Application Number: 16297599
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "161000"]

Abstract:
Disclosed herein are methods of preventing, inhibiting, reducing, or treating ischemia and reperfusion injury to tissues with glutarate compounds such as α-ketoglutarate.

Claim (Index 21):
A method of treating or reducing an ischemia-reperfusion (IR) injury to a tissue in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising:\n a therapeutically effective amount of a compound of Formula II: or a salt thereof, wherein:\n R 1  is hydrogen, halogen, \u2014CHO, \u2014OR 7 , \u2014NR 8 R 9 , \u2014COOR 7 , \u2014CONR 8 R 9 , \u2014SR 10 , substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; \n R 2  and R 3  are each independently hydrogen, halogen, \u2014CN, \u2014CHO, \u2014OR 7 , \u2014NR 8 R 9 , \u2014COOR 7 , \u2014CONR 8 R 9 , \u2014NO 2 , \u2014SR 10 , substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; \n or R 2  and R 3 , together with the atom to which they are bound, form an oxo; \n R 4  and R 5  are each independently hydrogen, halogen, \u2014CN, \u2014CHO, \u2014OR 7 , \u2014NR 8 R 9 , \u2014COOR 7 , \u2014CONR 8 R 9 , \u2014NO 2 , \u2014SR 10 , substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; \n R 6  is halogen, \u2014CN, \u2014CHO, \u2014OR 7 , \u2014NR 8 R 9 , \u2014COOR 7 , \u2014CONR 8 R 9 , \u2014NO 2 , \u2014SR 10 , substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl; and \n each R 7 , R 8 , R 9 , and R 10  is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; wherein each R 7  substituent is independently selected when two or more R 7  substituents are present, each R 8  substituent is independently selected when two or more R 8  substituents are present, each R 9  substituent is independently selected when two or more R 9  substituents are present, and each R 10  substituent is independently selected when two or more R 10  substituents are present; \n wherein the pharmaceutical composition is administered to the subject to treat or reduce IR injury to a tissue in the subject; and \n wherein the therapeutically effective amount is about 5-20 mg of the compound of Formula II, or the salt thereof, per kilogram weight of the subject.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 99.0
- Lexical Diversity: 1.08333
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15582748', '15522969', '16027029', '15123232', '15083836']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7715001152871174
- 35 USC 102 Novelty (BERT): 0.617421119451455
- Combined Prediction Score: 0.7560922157035511
- Mean Citation Score: 347.373964
- Max Citation Score: 555.04926
- Similarity Product: 528.5351063113869

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test